CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
ID: 347053Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347053

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-139.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21), aimed at developing medical countermeasures (MCMs) to address serious health risks from chemical threats. This funding opportunity focuses on exploratory research that generates preliminary data essential for the discovery and validation of novel treatment strategies, including the repurposing of FDA-approved products, to combat the effects of toxic chemical exposures resulting from terrorist activities or industrial accidents. The initiative underscores the importance of enhancing national security and public health preparedness against chemical incidents, with a funding ceiling of $275,000 available over a two-year period. Interested applicants must submit their proposals by May 30, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-139-Full-Announcement.html
    PAR-23-139.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), invites applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21). This funding opportunity focuses on developing medical countermeasures (MCMs) targeting serious health risks from chemical threats, which may arise from terrorist activities or industrial accidents. The initiative encourages exploratory research that produces preliminary data essential for further development of candidate MCMs. Eligible applicants include various educational institutions, nonprofits, and local governments, with a budget limit of $275,000 over two years. Applications should address the discovery of new treatment strategies, including repurposing FDA-approved products. Key dates highlight submission deadlines from April 30, 2023, through May 30, 2025. NIAID, NINDS, and other NIH components emphasize the significance of this research for national security and public health preparedness against chemical incidents. The proposal aims to advance knowledge and capability in effectively responding to public health emergencies involving chemical exposures.
    Similar Opportunities
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System." This initiative invites applications for basic research projects focused on understanding the mechanisms of toxicity of chemical warfare agents and toxic industrial chemicals that impact the nervous system, with the aim of developing potential therapeutic countermeasures for civilian exposure. The program is particularly significant in enhancing public health responses to chemical threats, emphasizing innovative and transdisciplinary research approaches. Up to four grants totaling $2 million are anticipated for fiscal year 2026, with applications due by 5 PM local time on October 17, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address health impacts from toxic chemical exposure. This funding opportunity aims to foster collaborations and innovative projects that can effectively mitigate adverse health effects, with an emphasis on the UG3/UH3 activity code for phased development. The NOFO is anticipated to be released in early 2025, with applications due by October 2025, and awards expected to be made by June 2026, marking a significant investment in public health safety. Interested applicants should prepare to align their proposals with the outlined objectives and timelines.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin," aimed at funding fundamental research on skin injuries caused by chemical threats recognized as public health risks. The initiative seeks to enhance understanding of the mechanisms leading to chemical-induced skin injuries and to identify potential therapeutic targets for medical countermeasure development, with a focus on examining two or more Chemicals of Concern, including at least one vesicant. This funding opportunity is crucial for advancing knowledge in the field of chemical threat response and wound healing, with an estimated funding amount of $1.25 million available for fiscal year 2025, allowing for up to five awards capped at $225,000 per year. Applications will open on January 16, 2025, and interested parties can direct inquiries to grantsinfo@nih.gov for further information.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Chemical Countermeasures Research Program (CCRP) Initiative, aimed at supporting research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, such as fentanyl and carfentanil. This initiative seeks to advance understanding of both immediate and delayed health impacts associated with these substances, emphasizing innovative research into toxicity mechanisms and the development of new therapeutic strategies. The program will provide up to four grants, with a maximum award of $300,000 annually over a potential five-year period, totaling an estimated $2 million in funding. Interested applicants, including various educational and nonprofit institutions, must submit their proposals by November 18, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Promoting a Basic Understanding of Chemical Threats to Skin," aimed at small businesses interested in researching the pathological mechanisms of skin injuries caused by toxic chemicals. The initiative seeks to elucidate the commonalities in the mechanisms of skin injuries from various vesicants, such as sulfur mustard and Lewisite, with the goal of identifying shared therapeutic targets and developing broad-spectrum medical countermeasures for mass casualty events. The estimated total program funding is $2,500,000, with approximately five awards expected, and interested applicants are encouraged to collaborate and prepare their proposals ahead of the anticipated application period, which is expected to open in early 2026. For further inquiries, potential applicants can contact Dr. Peter J. Koch at Peter.Koch@NIH.gov or by phone at 240-987-8325.
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is offering exploratory and developmental grants related to the World Trade Center Health Program (R21) to support research addressing diagnostic and treatment uncertainties for individuals affected by the 9/11 attacks. This funding opportunity aims to encourage innovative research projects that explore new areas of investigation, potentially leading to significant advancements in treatment effectiveness and diagnostic practices for those receiving monitoring and treatment under the James Zadroga 9/11 Health and Compensation Act. With an estimated total program funding of $30 million and an expected 60 awards, applicants can request funding ranging from $0 to $365,000. Interested parties should note that applications are due by 5:00 PM local time on February 12, 2026, and can direct inquiries to Dr. Eduardo O'Neill at 404-718-8844 or via email at fzt4@cdc.gov.
    Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products," aimed at supporting early-stage translational research for heart, lung, blood, and sleep disorders. This initiative employs a phased approach (R61/R33), where the R61 phase focuses on identifying and validating therapeutic candidates, while the R33 phase involves lead series identification for preclinical testing, emphasizing innovation and addressing therapeutic gaps. The total funding commitment is approximately $4.47 million per fiscal year from 2026 to 2028, with a maximum budget of $400,000 per year for each phase, and applications are due by December 23, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.